Skip to content
OpenCapital
Get started

Cytokinetics CYTK Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%—
Debt / equity2.2×—
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's increase (decrease) in accounts receivable?
Cytokinetics (CYTK) reported increase (decrease) in accounts receivable of -$10.94M in Q1 2026.
How has Cytokinetics's increase (decrease) in accounts receivable changed year-over-year?
Cytokinetics's increase (decrease) in accounts receivable increased by 25.3% year-over-year, from -$14.64M to -$10.94M.
What is the long-term trend for Cytokinetics's increase (decrease) in accounts receivable?
Over 3 years (2021 to 2025), Cytokinetics's increase (decrease) in accounts receivable has grown at a -71.4% compound annual growth rate (CAGR), from $47.4M to $1.11M.